{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-133273","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.783819+00:00","generated_at":"2026-05-20T02:49:08.798164+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Trevi Therapeutics terminates ATM prospectus; past sales $14.6M gross","bullets":["On June 2, 2025, Trevi terminated the August 15, 2023 ATM prospectus with Leerink Partners.","Sales Agreement remains in effect; no sales permitted until a new prospectus is filed.","As of March 31, 2025, Trevi sold 4,498,065 shares for gross proceeds of ~$14.6M.","No shares issued or sold under the Sales Agreement after March 31, 2025.","Commissions and fees on past sales totaled approximately $0.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-133273","json":"https://secwatch.observer/filing/0001193125-25-133273.json","markdown":"https://secwatch.observer/filing/0001193125-25-133273.md","text":"https://secwatch.observer/filing/0001193125-25-133273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525133273/0001193125-25-133273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525133273/d911843d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:49:08.798164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}